Cargando…

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic

Detalles Bibliográficos
Autores principales: Kearns, Donovan G., Chat, Vipawee S., Uppal, Shelley, Wu, Jashin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American Academy of Dermatology, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385551/
https://www.ncbi.nlm.nih.gov/pubmed/32735966
http://dx.doi.org/10.1016/j.jaad.2020.07.086
_version_ 1783563808418037760
author Kearns, Donovan G.
Chat, Vipawee S.
Uppal, Shelley
Wu, Jashin J.
author_facet Kearns, Donovan G.
Chat, Vipawee S.
Uppal, Shelley
Wu, Jashin J.
author_sort Kearns, Donovan G.
collection PubMed
description
format Online
Article
Text
id pubmed-7385551
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher by the American Academy of Dermatology, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73855512020-07-28 Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic Kearns, Donovan G. Chat, Vipawee S. Uppal, Shelley Wu, Jashin J. J Am Acad Dermatol JAAD Online by the American Academy of Dermatology, Inc. 2020-12 2020-07-28 /pmc/articles/PMC7385551/ /pubmed/32735966 http://dx.doi.org/10.1016/j.jaad.2020.07.086 Text en © 2020 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle JAAD Online
Kearns, Donovan G.
Chat, Vipawee S.
Uppal, Shelley
Wu, Jashin J.
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
title Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
title_full Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
title_fullStr Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
title_full_unstemmed Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
title_short Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
title_sort assessing the risk of adalimumab use for hidradenitis suppurativa during the covid-19 pandemic
topic JAAD Online
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385551/
https://www.ncbi.nlm.nih.gov/pubmed/32735966
http://dx.doi.org/10.1016/j.jaad.2020.07.086
work_keys_str_mv AT kearnsdonovang assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic
AT chatvipawees assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic
AT uppalshelley assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic
AT wujashinj assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic